中药与铂类化疗联用相互作用证据图谱:范围综述方案
BACKGROUND: The utilization of Chinese herbal medicine (CHM) has gained popularity and acceptance worldwide. Increasing use of CHM either as a stand-alone or an adjunctive treatment for cancers has given rise to increasing concern on potential herbal-drug reactions.…
要点
- 系统检索中英文数据库,纳入评估中药与铂类化疗联用的临床前及临床研究
- 采用PRISMA-ScR清单与范围综述框架,双人独立筛选以保证质量
- 旨在梳理中药-铂类化疗的配伍规律与草药-药物相互作用
核心结论
- 本范围综述将探讨中药与铂类化疗的配伍或联合规律,帮助理解两者联合治疗中的草药-药物相互作用。
- 识别中药草药-药物相互作用的活性成分并了解单用或联用时的药代与药效学,对患者安全性至关重要。
- 结果将为未来癌症治疗实践提供新的思路。
研究设计与样本
- 研究设计为范围综述方案(scoping review protocol)。
- 检索策略以PRISMA Scoping Reviews清单作为质量保证步骤。
- 所有检索记录由2名独立评审员筛选。
- 纳入涉及评估中药与铂类化疗同时使用的临床前研究和临床研究。
临床怎么用
- 本方案为范围综述计划,尚未报告结果,临床暂无可直接采用的推荐。
- 后续证据图谱可用于理解中药与铂类化疗联用的配伍规律与相互作用。
局限性
- 本文仅为研究方案,未提供实际研究结果与数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The utilization of Chinese herbal medicine (CHM) has gained popularity and acceptance worldwide. Increasing use of CHM either as a stand-alone or an adjunctive treatment for cancers has given rise to increasing concern on potential herbal-drug reactions. Possible combinatory effects are important to be explored in evaluating the rationality of integrating CHM and chemotherapy in clinical practice. This study aims to update the current knowledge on herbal-drug interactions (HDI) of the commonly used platinum-based chemotherapy (PtC) in cancer patients. METHODS: Systemic searches will perform on online databases (English and Chinese) to identify papers from inception until December 2019 for inclusion into the review. The search strategy will be following PRISMA Scoping Reviews Checklist as a quality assurance step. All records retrieved will be screened by 2 independent reviewers. The preclinical studies and clinical studies that involve in assessing the concurrent use of CHM and PtC will be considered. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses will be used as scoping review framework. DISCUSSION: This scoping review will explore the compatibility or combination rule of CHM-PtC and assist in understanding HDI in CHM-PtC co-treatment. Identification of active properties in CHM's HDI and understanding pharmacokinetics and pharmacodynamic of the CHM alone or as co-treatment are essential for patients' safety profile. It will provide a new insight for future practice in cancer treatment. STUDY REGISTRATION: This protocol has been registered in the Research Register (https://www.researchregistry.com/) with an unique registration number: reviewregistry790.
引用
- Liew AC, Chan SY, Lim RJ, et al. Evidence mapping of interactions on concomitant use of Chinese medicine and platinum-based chemotherapy: a scoping review protocol. Integr Med Res. 2020. PMID: 32382498. doi:10.1016/j.imr.2020.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。